Enhancement of breast cancer on pre-treatment dynamic contrast-enhanced MRI using computer-aided detection is associated with response to neo-adjuvant chemotherapy - 07/12/18
, Y. Ueno a, A. Aldis a, M. Seidler a, B. Mesurolle a, A. Omeroglu c, B. Gallix a, C. Reinhold a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Purpose |
To evaluate whether enhancement of breast cancer on pre-treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as evaluated semi-quantitatively using computer-aided detection (CAD) is associated with response to neo-adjuvant chemotherapy.
Materials and methods |
A total of 84 women, (mean age, 51±10 [SD] years; range: 30–73 years) with 84 breast cancers who underwent MRI before neo-adjuvant chemotherapy were included in this retrospective study. The proportion of each type of signal intensity-time curve (SITC) (type 1: persistent; type 2: plateau; Type 3: washout) within the tumor volume was quantified semi-automatically using a CAD system (Aegis®, Sentinelle medical, Toronto, Canada) and was compared to histological features of the tumors and to pathological response to neo-adjuvant chemotherapy.
Results |
Pathological complete response was obtained in 29 patients (35%). Proportion of SITC type 1 was greater in non-responders (P=0.019) while proportion of SITC type 3 was greater in responders (P=0.04). Sensitivity, specificity, and accuracy of proportion of SITC type 1 for the identification of incomplete response on pathology were 42% (95% CI: 29%–56%), 90% (95% CI: 73%–98%), and 59% (95% CI: 48%–70%), respectively.
Conclusion |
Proportion of SITC type 1 (persistent) in breast cancers on pre-treatment MRI as semi-automatically quantified using a CAD system is associated with absence of pathological complete response to neo-adjuvant chemotherapy with good specificity.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Pre-treatment MRI, Computer-aided detection, Neo-adjuvant chemotherapy, Tumor response evaluation
Plan
| ☆ | This manuscript has not been published or submitted simultaneously elsewhere. |
Vol 99 - N° 12
P. 773-781 - décembre 2018 Retour au numéro
Article précédent
- Contents 2 pages
- Microwave ablation combined with doxorubicin enhances cell death via promoting reactive oxygen species generation in breast cancer cells
- P. Kong, L. Chen, X. Shi, H. Pan, M. Yu, H. Ge, J. Zhu, G. Ma, L. Li, Q. Ding, W. Zhou, S. Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.